What Is DSIP? Nonapeptide Sequence and Neuroendocrine Signalling Research

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide — Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu — first isolated from rabbit cerebral venous blood in the 1970s. This page covers the molecule itself: sequence, physicochemical identity, distribution, and the signalling pathways published research has examined.

Sequence and Molecular Identity

| Property | Value | | --- | --- | | Sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu | | Residues | 9 (nonapeptide) | | Molecular weight | ≈849.9 Da | | Terminal residues | Tryptophan (N-terminus), glutamate (C-terminus) | | Net charge | Acidic at physiological pH (two carboxylate side chains) | | Class | Naturally occurring neuropeptide |

Three structural features dominate the analytical literature. The position-1 tryptophan gives the peptide its UV absorbance handle at 280 nm and is the main photodegradation liability. The glycine-rich core (positions 3, 4, 8) leaves the backbone conformationally flexible, which is one reason a single defined binding conformation has been difficult to establish. The aspartate and glutamate side chains give the molecule its acidic character and its chromatographic behaviour on reverse-phase separation.

Endogenous Distribution

Immunoreactivity studies report DSIP-like material in the hypothalamus, limbic structures, pituitary, and a range of peripheral tissue rather than in one localised region. This wide distribution is frequently contrasted with neuropeptides that act within a defined nucleus, and is part of the reason its measured effects span several unrelated endpoint families.

Signalling Pathways Examined

No characterised receptor. The central mechanistic fact about DSIP is negative: no dedicated high-affinity receptor has been identified. Binding-site work has not converged, and mechanistic claims in the literature are accordingly framed as provisional.

GABAergic and glutamatergic modulation. Reported influence on inhibitory and excitatory neurotransmitter release rather than direct receptor agonism, which is the usual explanation offered for measured EEG changes that differ in character from classical receptor agonists.

Hypothalamic CRH signalling. The best-supported pathway in the record. DSIP pretreatment in animal stress models attenuates ACTH and corticosterone rises, placing its action somewhere upstream in the hypothalamic-pituitary-adrenal cascade.

Opioid-system interaction. Proposed on the basis of antagonist-sensitivity observations in animal models; the supporting data are thinner than for the HPA-axis findings.

Antioxidant enzyme expression. Upregulation of SOD, catalase and glutathione peroxidase measured in tissue under oxidative challenge, independent of the neurological endpoints.

Blood-Brain Barrier Passage

Radiolabelled tracer studies report that peripherally administered DSIP reaches central compartments, with accumulation measured in hypothalamic and limbic regions. Small size and the flexible glycine-rich backbone are the properties usually cited. This property is what makes the peptide tractable for central-endpoint work in animal models without intracerebral delivery.

Analytical Identity and Handling

DSIP is supplied as lyophilised material and identified analytically by mass (≈849.9 Da) and by reverse-phase retention against a reference standard, with the tryptophan chromophore providing the detection handle. Lyophilised material is held at −20 °C protected from moisture; reconstituted solutions are refrigerated, protected from light, and used within a few weeks. Sealed vials with their batch documentation are listed on the DSIP catalog listing.

What the Name Does and Does Not Mean

"Delta sleep-inducing" describes the EEG context of the 1970s isolation experiment, not a validated functional classification. Published work measuring EEG endpoints has produced mixed results across species and laboratories, while the HPA-axis and stress-signalling measurements have proved more reproducible. Reading the literature accurately means tracking which endpoint each study measured rather than assuming the name describes the compound's principal characterised action.

Research Use Only. This content is intended for laboratory and research purposes only. Not for human consumption, diagnosis, or treatment.

References

1. Schoenenberger GA, Monnier M. "Characterization of a delta-electroencephalogram(-sleep)-inducing peptide." *Proc Natl Acad Sci USA*. 1977;74(3):1282–1286.
2. Graf MV, Kastin AJ. "Delta-sleep-inducing peptide (DSIP): an update." *Peptides*. 1986;7(6):1165–1187.
3. Kovalzon VM, Strekalova TV. "Delta sleep-inducing peptide: a still unresolved riddle." *J Neurochem.* 2006;97(2):303–309.
4. Charnay Y, et al. "Distribution of delta sleep inducing peptide-immunoreactivity in the human brain." *J Chem Neuroanat.* 1990;3(5):397–409.

Running the numbers for a protocol? Use the research calculators to convert mg, mL, and syringe units.